Compare QUIK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | HELP |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Canada |
| Employees | 51 | 50 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 214.5M |
| IPO Year | 1997 | N/A |
| Metric | QUIK | HELP |
|---|---|---|
| Price | $21.86 | $4.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.00 | ★ $51.50 |
| AVG Volume (30 Days) | 425.9K | ★ 567.2K |
| Earning Date | 05-12-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $3.76 |
| 52 Week High | $24.33 | $8.55 |
| Indicator | QUIK | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 53.98 |
| Support Level | $17.30 | $4.32 |
| Resistance Level | $23.61 | $4.75 |
| Average True Range (ATR) | 1.88 | 0.30 |
| MACD | -0.25 | 0.08 |
| Stochastic Oscillator | 61.18 | 91.00 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.